Getting Product In and Out: Distribution Licensing, Trade Agreements, and the Tax Mechanics of a Singapore Biomedical Base

9.1 Three Gates, Not One

A European firm evaluating Singapore as a biomedical base tends to think of market entry as a single regulatory event: get the product approved, then sell it. The reality for distribution and trade is that three separate gates stand between a decision to operate from Singapore and the first carton leaving the warehouse, and they are administered by three different parts of government with three different logics.

The first gate is held by the Health Sciences Authority, Singapore’s health products regulator. It governs who may import and who may wholesale health products, and it does so through licences tied to activities rather than to products. A firm does not earn the right to handle therapeutic products by registering one drug; it earns that right by holding a dealer’s licence and passing the quality audit that precedes it.

The second gate is held by Singapore Customs and shaped by the trade agreements Singapore has signed. This gate governs the physical crossing of the border: the declaration, the permit, the tariff treatment, and the rules that determine whether a shipment qualifies for preferential treatment under an agreement. It is here that the EU-Singapore Free Trade Agreement and the Regional Comprehensive Economic Partnership operate, and it is here that European firms most often misread what those agreements actually do for them.

The third gate is held by the Inland Revenue Authority of Singapore and concerns the Goods and Services Tax. This gate does not stop product moving, but it determines the cash-flow cost of moving it. An import attracts GST at the point of entry. For a firm that imports to re-export, that is dead money tied up between import and export, and Singapore offers two principal schemes to release it.

These three gates are the subject of this chapter. They are operational, not strategic, and a European owner-operator can be forgiven for finding them tedious. But the firms that come unstuck in Singapore rarely fail on strategy. They fail on the gate they did not budget for: the Responsible Person they could not recruit, the GDP audit they were not ready for, the GST they paid upfront and waited months to recover, or the ASEAN registration they assumed the Singapore licence would carry and which it did not.

The honest framing of this chapter is that Singapore is unusually good at making these three gates predictable, and that predictability is the product. It is not, however, free, and for some European use cases the cost of the predictability outweighs its value. This chapter aims to let the reader tell which case applies to them.

9.2 The First Gate: HSA Dealer’s Licensing and Good Distribution Practice

Activity-based licensing

Singapore regulates the supply chain for therapeutic products through what the Health Sciences Authority calls an activity-based licensing framework. A company that imports therapeutic products needs a Therapeutic Product Importer’s Licence, and a company that wholesales them needs a Therapeutic Product Wholesaler’s Licence.¹ The two activities are licensed separately because they are different activities, though a firm doing both can bundle the applications.²

The distinction that catches European firms is between holding a product registration and holding a dealer’s licence. They are not the same permission. A firm can be the registrant of a product in Singapore and still not be permitted to import or wholesale it; conversely, if the registrant outsources import and wholesale to another company, it is that other company, not the registrant, that must hold the dealer’s licences and meet the associated standard.³ The licence attaches to the activity and to the company performing it.

For a firm that imports active ingredients rather than finished therapeutic products, a parallel regime applies, with its own importer’s and wholesaler’s licences for active ingredients.⁴ A European fine-chemicals or active-pharmaceutical-ingredient supplier setting up a Singapore holding and distribution function should not assume the therapeutic-product licences cover ingredient activity; the categories are distinct.

The Good Distribution Practice audit

Behind the dealer’s licence sits the substantive requirement: compliance with the Good Distribution Practice standard. GDP compliance is mandatory for all importers and wholesalers of therapeutic products, and a licence is not granted until the firm has been audited against the standard and found to comply.⁵ When an application is received, the Authority schedules a GDP audit of the firm’s premises, and the licence is approved and issued only after a satisfactory audit close-out, on the Authority’s published timeline of ten working days from that close-out.⁶

This sequencing matters for project planning. The audit is not a formality that follows the licence; it is the gate to the licence. A firm cannot move product first and tidy up its quality system later. The warehouse, the cold-chain equipment, the temperature monitoring, the standard operating procedures, and the records must all exist and function before the auditor arrives, because the auditor’s finding is what unlocks the licence.

There is a narrow set of restricted activities for which the GDP audit is waived, including importing therapeutic products solely for export, for supply to ships or aircraft leaving Singapore, or for non-clinical use.⁷ A European firm whose Singapore function is purely a re-export trans-shipment node, never placing product on the local market, should examine whether it falls within these restricted activities, because if it does, the licensing burden is materially lighter. Most firms that want a genuine regional distribution base do not fall within them.

The Responsible Person

Every importer’s or wholesaler’s licence must name a Responsible Person. This is not an administrative contact; it is a statutory role. Under the Health Products (Therapeutic Products) Regulations, the licensee must appoint and name one or more Responsible Persons on the face of the licence, with at least one contactable at all times.⁸ The Responsible Person is the individual who implements and maintains the quality management system that meets the GDP standard,⁹ and the role is structured so that this person can make quality decisions independently of commercial pressure.

The qualification bar varies with what the firm handles. For general therapeutic-product operations, the Responsible Person needs a relevant scientific qualification and GDP training. But where the licence covers prescription-only, pharmacy-only, or unregistered therapeutic products, the Responsible Person must be a registered pharmacist.¹⁰ That single requirement is, in the author’s observation, one of the most underestimated constraints in the whole chapter, and §9.7 returns to it as a worked staffing problem.

The separate and harder regime for controlled drugs

A European firm whose portfolio includes opioids, certain stimulants, or other substances scheduled under the Misuse of Drugs Act faces a regime that is materially more demanding than the standard dealer’s licence. Controlled drugs are regulated jointly by the Health Sciences Authority and the Central Narcotics Bureau, and Singapore applies the International Narcotics Control Board’s quota allocations under the United Nations drug-control conventions.¹¹ Any person intending to import, export, or tranship controlled substances must declare to the Central Narcotics Bureau for approval well in advance of the shipment, through the Bureau’s dedicated licensing system, and only then apply through TradeNet for the customs permit.¹²

The practical character of this regime is that the controlled-drug import licence is consignment-specific: it does not function like an annual dealer’s licence that covers a flow of business, but as a per-shipment permission tied to an allocated quota. A firm building a Singapore distribution model around controlled substances should plan its operating rhythm around this consignment-by-consignment, quota-bound reality rather than around the smoother cadence of standard therapeutic-product wholesaling.

[DAVID: This sub-section would benefit from one or two sentences of practitioner observation on how European firms with controlled-substance portfolios actually experience the CNB quota timing in practice, drawn from any transactional or advisory exposure you have had. If you have none, we leave it at the sourced description above, which is sufficient and honest.]

9.3 The Second Gate: How Goods Actually Cross the Border

TradeNet and the competent-authority declaration

Singapore clears imports through TradeNet, a single-window electronic portal that connects the trader, Singapore Customs, and the relevant competent authorities. For health products, this means a declaration that satisfies both Customs and the Health Sciences Authority in one submission. The Authority sits in the TradeNet system as a competent authority, and a firm importing controlled health products must declare the appropriate HSA product code alongside the Harmonised System classification of the goods.¹³

The product code is the mechanism by which the system enforces the first gate at the moment of the second. A declarant importing registered therapeutic products or medical devices declares them under the relevant product code and must supply the corresponding licence, registration, and approval numbers in the designated fields of the permit application; missing or incomplete codes delay or cause rejection of the application.¹⁴ In other words, a firm cannot clear a shipment of registered therapeutic products through Customs without already holding and citing the dealer’s licence and product registration. The customs gate checks that the licensing gate has been passed.

Notably, a range of lower-risk health products, including cosmetic products, health supplements, and certain quasi-medicines, are not subject to the Authority’s pre-import licensing and are therefore no longer declared with HSA product codes at all.¹⁵ A European firm whose Singapore-based portfolio is concentrated in these categories faces a far lighter border regime than a firm handling registered therapeutic products, and should size its compliance function accordingly rather than over-building for a burden it does not carry.

The EU-Singapore Free Trade Agreement, read correctly

European firms approach the EU-Singapore Free Trade Agreement expecting it to be the instrument that lowers the cost of shipping their products into Singapore. For most industrial and biomedical goods, it is not, and understanding why is the single most useful piece of trade-agreement literacy in this chapter.

The Agreement entered into force on 21 November 2019, the first free trade agreement between the European Union and a member of ASEAN.¹⁶ It is a comprehensive agreement that removes tariffs on both sides and addresses non-tariff barriers, services, procurement, and intellectual property.¹⁷ But the asymmetry that matters to a European importer is this: before the Agreement, almost all goods originating in the European Union could already enter Singapore free of customs duties.¹⁸ Singapore is a near-zero-tariff economy by long-standing policy. The tariff-elimination story that the Agreement is famous for runs the other way: it is about goods originating in Singapore entering the European Union, where roughly 84 percent of imports from Singapore became duty-free on entry into force and the remainder were phased out over the following years.¹⁹

The practical implication for a European pharmaceutical or device firm is that the Agreement does not meaningfully reduce the duty cost of bringing its products into Singapore, because that duty cost was already close to zero. Where the Agreement earns its place for such a firm is on the export leg, if and when the firm manufactures or substantially processes in Singapore and ships finished product back into the European Union, and in the regulatory-cooperation provisions discussed next. A firm that builds a business case on EUSFTA-driven import savings into Singapore has misread the Agreement.

The Agreement’s rules of origin operate through a self-certification system. Rather than obtaining paper preferential certificates of origin, a qualifying exporter makes an origin declaration directly on a commercial document such as the invoice.²⁰ This is administratively lighter than certificate-based regimes, and it is one of the genuine conveniences of the Agreement for firms that do qualify for preferential treatment on the export leg.

The regulatory-cooperation provisions that actually help biomedical firms

The part of the EU-Singapore Free Trade Agreement most relevant to a biomedical firm is not the tariff schedule but Annex 2-C, which addresses pharmaceuticals and medical devices. It commits both parties to base their technical regulations for these products on international standards, and to keep procedures for listing, pricing, and reimbursement objective, fair, reasonable, and non-discriminatory.²¹ For a European firm whose regulatory dossiers are built to international norms, this commitment reduces the risk of encountering idiosyncratic local technical requirements, which is a more durable benefit than a tariff line.

The Regional Comprehensive Economic Partnership: what it does and does not deliver

A European firm using Singapore as a regional base will hear a great deal about the Regional Comprehensive Economic Partnership, the agreement among the ten ASEAN states and five partners, including China, Japan, South Korea, Australia, and New Zealand. It entered into force on 1 January 2022 and provides for tariff elimination on around 92 percent of goods traded among its parties.²²

Two features of the Partnership are genuinely useful for a Singapore-based distributor. The first is regional cumulation in the rules of origin: a manufacturer can source inputs from across the member states and count them toward originating content, which suits the regionally dispersed supply chains common in biomedical manufacturing.²³ The second is a set of trade-facilitation commitments on customs clearance, including the much-cited provision that perishable goods should be released in the shortest possible time and, to the extent possible, within six hours of arrival.²⁴

That six-hour provision deserves a careful reading, because it is routinely overstated. The agreement text frames it as a best-endeavours commitment, expressed as release “to the extent possible” and “in the shortest possible time,” not as an absolute guarantee enforceable on every shipment.²⁵ For temperature-sensitive biologics and advanced therapies, the provision is a helpful direction of travel rather than a contractual assurance that any given consignment will clear within six hours, and a firm planning cold-chain timelines should not treat it as one.

The honest assessment of the Partnership for a European biomedical firm is that its tariff benefits are real but modest where Singapore is the base, because Singapore’s own tariffs are already near zero, and its facilitation benefits are useful but soft. The Partnership is not the reason to choose Singapore. It is a background convenience for a firm that has chosen Singapore for other reasons.

9.4 Where the Trade Agreements Do Not Reduce Friction

It is worth being direct about the limits of both agreements, because the marketing around free trade agreements tends to imply a frictionlessness that the agreements do not deliver.

The first limit is that preferential treatment is never automatic. A firm must establish that its goods qualify under the relevant rules of origin, document that qualification, and make the correct declaration. Where a product’s inputs come from outside the agreement’s members, or where the processing in Singapore is insufficient to confer origin, the goods do not qualify, and the firm pays the most-favoured-nation rate regardless of the agreement’s existence. For a firm whose value-add in Singapore is light, the origin rules may simply not be satisfiable.

The second limit is that the Regional Comprehensive Economic Partnership, despite its scale, sees relatively low utilisation in some markets because commercial operators often find that older bilateral agreements or the ASEAN-plus-one agreements deliver equivalent or better treatment with rules they already understand. The Partnership’s preferences sometimes carry additional domestic-value-content conditions in particular markets, and the administrative work of registering factories, preparing manufacturing cost statements, and obtaining the necessary origin documentation can outweigh the marginal tariff saving. A firm should check, market by market, whether the Partnership is actually the best instrument for the specific trade lane, rather than assuming the newest and largest agreement is automatically the most advantageous.

The general lesson is that a trade agreement is a conditional offer, not a blanket discount. The conditions are the rules of origin and the documentation, and meeting them is work. For a Singapore-based firm whose goods clearly qualify and whose trade lanes run to markets where the agreement is genuinely the best instrument, that work pays for itself. For a firm at the margin, it may not.

9.5 The ASEAN Registration Reality: What the Singapore Base Does Not Buy

This is the section where honesty matters most, because the misconception it corrects is both common and expensive.

A European firm is frequently told that establishing a Singapore drug import and wholesale licence is a strategic move that opens the wider Southeast Asian market. The claim is half true in a way that makes it dangerous. Singapore is an excellent base from which to coordinate regional distribution, and its connectivity, rule of law, and regulatory quality are real advantages for a regional hub. But a Singapore dealer’s licence and a Singapore product registration confer no automatic right to sell that product in any other ASEAN market. Regional registration does not flow from a Singapore base.

Each ASEAN market maintains its own national medicines regulator, its own product registration process, its own dossier requirements, its own timelines, and its own fees. A product registered with the Health Sciences Authority is registered in Singapore. To sell it in Indonesia, the firm registers with Indonesia’s regulator; to sell it in Vietnam, Thailand, the Philippines, or Malaysia, the firm registers with each respective national authority, on each authority’s terms. There is no single regional registration that a Singapore base unlocks.

What ASEAN-level cooperation does provide is partial and technical rather than a single market. The ASEAN Sectoral Mutual Recognition Arrangement for the inspection of manufacturers of medicinal products allows the mutual recognition of Good Manufacturing Practice inspection outcomes among participating members, which can reduce duplicate manufacturing inspections. That is a meaningful convenience on the manufacturing-inspection side. It is not product registration, and it does not let a firm sell a Singapore-registered product across the region on the strength of the Singapore registration.

The practical consequence for planning is significant. A firm whose Singapore business case rests on the assumption that one registration serves the region has mis-budgeted both cost and time. Each target market is a separate registration project with its own multi-month, multi-fee timeline. The correct way to think about the Singapore base is as the coordinating and distribution centre for a portfolio of separate national registrations, not as the holder of a regional registration that does not exist. A firm whose entire commercial case is selling into a single large ASEAN market, and which does not need a regional coordination function, should ask hard whether it needs a Singapore base at all, or whether it should simply register and distribute in that one market directly. For that firm, Singapore may be an expensive detour.

9.6 The Third Gate: GST and the Schemes That Relieve It

The working-capital problem

Singapore levies Goods and Services Tax at 9 percent, and the tax is due on goods at the point of import. Under the ordinary rule, a firm pays GST to Singapore Customs when goods enter, and recovers it later through its GST return.²⁶ For a firm that imports in order to re-export, this creates a working-capital problem: the firm’s onward supplies are zero-rated exports that generate no output GST to offset the cash it laid out at import, so the import GST sits as dead money from import until refund.²⁷ For a high-value, high-volume biomedical distribution operation, the sums tied up this way can be substantial.

Singapore’s response is a set of schemes that suspend the import GST rather than charging and refunding it. Two matter most for a biomedical firm.

The Major Exporter Scheme

The Major Exporter Scheme allows an approved business to import non-dutiable goods with GST suspended, so the cash is never laid out at the border.²⁸ To qualify, a business must be GST-registered, active and solvent, importing goods for its business, and must meet an export threshold: its zero-rated supplies must account for more than 50 percent of its total supplies, or the value of its zero-rated supplies must exceed S$10 million over a 12-month period.²⁹ The scheme is granted subject to internal-control and compliance requirements, may require a banker’s guarantee, and must be renewed; a business that falls below the qualifying threshold is not invited to renew.³⁰

For a European firm running a genuine regional re-export operation from Singapore, the Major Exporter Scheme is usually the first GST relief to examine, because the export-heavy profile that makes Singapore attractive as a hub is precisely the profile the scheme is designed for. The scheme does not reduce the firm’s ultimate tax; it removes the cash-flow drag of paying and reclaiming.

The Approved Contract Manufacturer and Trader Scheme

The Approved Contract Manufacturer and Trader Scheme is the relevant relief for a different model: a firm that processes or manufactures in Singapore on behalf of an overseas client. Under ordinary rules, value-added services performed on a client’s goods that remain in Singapore would attract GST, and an overseas client that is not GST-registered could not recover it. The scheme allows an approved contract manufacturer to disregard the supply of value-added activities, such as processing, assembly, and testing, to a non-GST-registered overseas client, where the treated goods are exported, delivered to another approved person under the scheme, or delivered to the final customer of the overseas client.³¹ No GST is charged on the fees to the overseas client, and the scheme also provides import GST suspension for goods the firm imports for its business and for goods belonging to an overseas principal handled in an agency capacity.³²

The scheme is targeted by industry. The Inland Revenue Authority states that it is currently available to contract manufacturers in the biomedical industry for active pharmaceutical ingredient manufacturing, with other biomedical segments considered on a case-by-case basis.³³ A European firm establishing a Singapore contract-manufacturing operation for an overseas group company should treat the scheme as central to its tax planning, but should confirm its specific activity’s eligibility with the Authority rather than assuming automatic coverage.

Relief for clinical trial materials

A firm running or supplying clinical trials from Singapore has a further, specific relief. Clinical trial materials imported for regulated clinical trials, including medicinal products, certain cell, tissue, and gene therapy products, therapeutic products, and their placebos, may be eligible for GST relief on import, as may such materials imported for destruction or for export for use in trials overseas.³⁴ The relief is claimed through a specific TradeNet permit type, and clinical trial materials must be declared separately from non-qualifying goods, which require their own GST-paid import permit.³⁵ For a European biotechnology firm using Singapore as a trial site or a regional supply point for trial materials, this relief removes the GST cost from a category of imports that would otherwise carry it.

9.7 A Worked Staffing and Cash-Flow Problem

Consider a representative case: a mid-sized European specialty pharmaceutical firm, headquartered in Germany, deciding to consolidate its Asia-Pacific distribution through a Singapore entity. The portfolio is prescription-only finished therapeutic products, imported from European manufacturing sites and re-exported to a set of national distributors across the region, with a portion also sold into the Singapore market. Annual import value through the Singapore entity is on the order of S$40 million.

The licensing gate requires a Therapeutic Product Importer’s Licence and, because the firm wholesales onward, a Therapeutic Product Wholesaler’s Licence, each preceded by a Good Distribution Practice audit of the Singapore warehouse and cold-chain. Because the products are prescription-only, the firm’s Responsible Person must be a registered pharmacist, contactable at all times, with the authority to make quality decisions independently. This is the binding constraint. The pool of registered pharmacists in Singapore who also have GDP and distribution experience and are willing to carry statutory Responsible Person liability is finite, and the firm is competing for that pool with every other distributor in the market. In the author’s observation of the broader market, the recurring weaknesses the regulator identifies in this role, overburdening a single person across multiple functions, insufficient deputy arrangements, and too little time allocated to discharge the regulatory duties, all trace back to the difficulty of recruiting and retaining qualified Responsible Persons. A firm that treats this as an afterthought to be solved after the lease is signed will find its whole timeline held hostage to a single hire.

[DAVID: This worked example would be materially stronger with your practitioner observation on the Responsible Person recruitment market specifically, the realistic salary band, lead time to hire, and whether firms typically recruit before or after securing premises. Insert here. The sourced regulatory description above stands on its own if you prefer not to add market specifics.]

The cash-flow gate, by contrast, has a clean answer. On S$40 million of annual imports at 9 percent GST, a firm without relief would cycle roughly S$3.6 million of GST through the working-capital account over a year, paid at import and recovered on return, with the float cost depending on the lag. Because the firm’s profile is export-heavy, with zero-rated re-exports comfortably exceeding both the 50 percent and the S$10 million thresholds, it qualifies for the Major Exporter Scheme, and the import GST is suspended rather than paid and reclaimed. The float cost effectively disappears. The scheme does not change the firm’s tax liability; it changes the firm’s cash position, and on these numbers the difference is the carrying cost of several million Singapore dollars across the year.

The lesson of the worked case is the asymmetry between the two gates. The tax gate is genuinely well-engineered and, for the right profile, closes cleanly with a scheme designed for exactly that profile. The licensing gate, and specifically the Responsible Person within it, is the gate that actually determines whether and when the firm can operate, and it is the one a European entrant is least likely to have budgeted for.

9.8 What Is Changing, and What to Watch

Several elements of this chapter rest on figures and rules that move, and a reader should treat them as current-as-of-publication rather than fixed.

The GST rate reached 9 percent and is the rate to verify against the Inland Revenue Authority at the time of any decision, because the cash-flow arithmetic in §9.7 scales directly with it. The Good Distribution Practice standard itself is revised periodically, including a revision that clarified requirements for handling active pharmaceutical ingredients in alignment with the active-ingredients regulations, so a firm should work from the current published standard rather than an older edition. On the manufacturing side, the Authority has made Good Manufacturing Practice compliance evidence a hard requirement for active-ingredient manufacturers supporting drug applications, which a firm sourcing or manufacturing active ingredients should confirm in its current form.

On trade, the EU-Singapore relationship continues to deepen beyond the goods agreement; the parties signed a digital trade agreement in 2025, and the investment-protection agreement that complements the free trade agreement awaits full ratification. None of this changes the goods-and-tariff analysis above, but a firm whose model has a significant digital or data component should track the digital trade agreement separately.

The general discipline this chapter recommends is to verify the four or five load-bearing numbers, the GST rate, the Major Exporter Scheme thresholds, the current GDP standard edition, and the current state of any controlled-drug quota relevant to the portfolio, directly against the administering authority before committing capital. The structure of the regime is stable; the specific figures are not.

9.9 The Recurring Mistakes

European firms make a consistent set of errors on this material. They are listed here because a reader who absorbs nothing else from the chapter can still avoid the expensive ones.

Assuming the product registration is the licence. A Singapore product registration does not entitle a firm to import or wholesale. The dealer’s licences are separate permissions tied to activities, and they are held by whichever company actually performs the activity.

Treating the GDP audit as a post-licence formality. The audit is the gate to the licence, not a follow-up to it. The quality system, the warehouse, and the cold-chain must be operational before the auditor arrives, because the audit finding is what unlocks the licence.

Under-resourcing the Responsible Person. The statutory role, and the registered-pharmacist requirement for prescription-only products, is the binding constraint on the whole timeline. Recruiting late, or loading the role onto a person already stretched across other functions, is the most common cause of avoidable delay and of audit findings.

Misreading the EU-Singapore Free Trade Agreement. The Agreement does not meaningfully cut the cost of importing European products into Singapore, because Singapore was already a near-zero-tariff destination for EU goods. Its tariff benefit runs on the export leg and on regulatory cooperation, not on cheaper imports into Singapore.

Over-relying on the RCEP six-hour rule. The perishable-clearance provision is a best-endeavours commitment, not a guarantee. A cold-chain timeline for biologics should not be built on the assumption that every consignment clears within six hours.

Assuming the Singapore licence opens ASEAN. Regional registration does not flow from a Singapore base. Each ASEAN market is a separate registration project with its own regulator, dossier, timeline, and fees. A firm that budgets one registration for the region has mis-budgeted by a wide margin.

Paying GST at import when a scheme would suspend it. An export-heavy distribution operation that does not apply for the Major Exporter Scheme, or a contract manufacturer for overseas clients that does not apply for the Approved Contract Manufacturer and Trader Scheme, is leaving working capital on the table for no reason. The schemes exist for exactly these profiles.

Forgetting that controlled drugs are a different regime. A portfolio that includes scheduled substances faces consignment-specific, quota-bound import permissions administered jointly by the Health Sciences Authority and the Central Narcotics Bureau, with advance declaration timelines. This cannot be run on the rhythm of standard wholesaling.

References

Declarations

Competing interests: The author is a licensed real estate agent (Council for Estate Agencies, Singapore) affiliated with OrangeTee & Tie Pte Ltd, and a Singapore Mediation Centre-accredited mediator. The author has commercial interests in industrial and commercial real estate transactions facilitated through OrangeTee & Tie. These interests are openly disclosed. The analysis in this chapter has been written to be useful to the reader irrespective of whether the reader subsequently engages the author’s transactional services.

Funding: This work received no external funding.

Methodology: This chapter draws on the published guidance and statutory instruments of the Singapore agencies that administer the three regulatory gates it describes: the Health Sciences Authority for dealer’s licensing, Good Distribution Practice, and the Responsible Person requirement; Singapore Customs and the Central Narcotics Bureau for import declaration and controlled-substance procedures; the Inland Revenue Authority of Singapore for Goods and Services Tax treatment and the Major Exporter and Approved Contract Manufacturer and Trader Schemes; and the Ministry of Trade and Industry, Enterprise Singapore, and the European Commission for the EU-Singapore Free Trade Agreement and the Regional Comprehensive Economic Partnership. Each load-bearing factual claim has been verified against the administering authority’s own publication at the point of drafting. Where the underlying research material asserted figures that could not be confirmed against a primary source, those figures were omitted rather than reproduced. Practitioner observations are identified as such.

Currency of analysis: The analysis is current as of the date of publication. The Goods and Services Tax rate, the Major Exporter Scheme thresholds, the edition of the Good Distribution Practice standard, controlled-drug quotas, and the state of ratification of related EU-Singapore instruments are all subject to change and should be verified against the administering authority before any commitment of capital.

About the Author

David Hoicka is a Singapore-licensed real estate agent (Council for Estate Agencies) affiliated with OrangeTee & Tie Pte Ltd, with a specialisation in industrial and commercial property for European inbound investment. He is also a Singapore Mediation Centre-accredited mediator, a civil engineer (Bachelor of Science, Massachusetts Institute of Technology), and the founder and publisher of Singapore Mediation Solutions, an academic publisher registered with Crossref (DOI prefix 10.66404) and with the National Library Board of Singapore. He has lived in Singapore as a permanent resident for over twenty-one years.

Scholarly identifiers: ORCiD 0000-0001-9082-0720; Wikidata Q137455251; ISNI 0000 0005 2886 676X; Google Scholar profile available.

About the Publisher

Singapore Mediation Solutions is an open-access scholarly publisher specialising in practical and analytical works for cross-border commercial practitioners with a focus on Asia-Europe industrial and commercial relations. Singapore Mediation Solutions is registered with Crossref (DOI prefix 10.66404), is a Singapore publisher with NLB-assigned ISBNs, and deposits all works in Zenodo for permanent open-access availability and in OCLC WorldCat for library catalogue accessibility.

Confidential Consultation

Readers who would like to discuss the licensing, customs, and tax structuring of a Singapore biomedical distribution or contract-manufacturing base in confidence may contact the author directly. The preferred channels are Signal and Telegram for confidentiality and ease of cross-border communication. Direct email is also available. Contact details are listed on singaporescienceparks.com. Initial consultations are conducted without obligation; the author’s role as principal advisor and the relationship to OrangeTee & Tie transactional execution are set out in a written engagement letter before any onward referrals are made.

---

Chapter DOI: biobook-ch09 (to be assigned upon Crossref deposit) Zenodo deposit: pending Published by Singapore Mediation Solutions, Singapore Open access under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)